Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

Pancreatic tumors reprogram immune cells that normally shut down tumor-killing cells, according to a team at Oregon Health & ...

A new pill could be the future of treatment late-stage pancreatic cancer in the U.S., nearly doubling the length patients ...

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are ...

New experimental medications seem to extend survival with the hard-to-treat cancer.

CBS News New York's John Elliott spends the morning at the Lustgarten Foundation's Spring Walk for Pancreatic Cancer Research ...

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.

A medical oncologist called the late-stage clinical trial results “remarkable,” though Sasse said the drug means his body ...

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a ...

Former Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data ...

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event ...